Articles that tag SDGR but are mainly about other companies.
Listed as a prominent participant in the competitive biosimulation landscape with strong market positioning, benefiting from industry-wide growth driven by AI integration and broader therapeutic applications.
Featured as a notable company in the generative AI drug discovery space, benefiting from increased adoption of AI-driven molecule generation and drug design tools.
Established player using physics-based computational chemistry approach with software licensing and pipeline advancement. Presented as an alternative modeling philosophy without specific performance commentary.
Established software business with recurring revenue ($255.9M, 23.3% growth) and improving profitability trajectory, but still reporting significant losses ($103.3M). Positive free cash flow ($12.5M) and lower valuation (4.3x P/S) are offset by ongoing losses and software sales cycle unpredictability. Analyst prefers this over Recursion but wouldn't buy currently.
Company has a rare combination of real software revenue ($256M in 2025) with strong growth guidance (10-15% ACV growth expected in 2026), solid balance sheet supporting operations through 2028, and partnerships with major pharmaceutical companies. Provides revenue foundation most early-stage biotech lacks.
Listed as a leading biosimulation company in North America, well-positioned to capitalize on the market's robust expansion driven by increasing R&D spending and adoption of AI and machine learning-enabled modeling platforms.
Articles and sentiment ratings from Massive / Polygon. Sentiment is the provider's model rating for this company, not Gainbot's view.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
